URL: www.eyefox.com/7342 zurück 18th Congress European Society Congress of Retina Specialists 2018 Kongress 20.09.2018, 09:00-23.09.2018, 13:30 1020 Wien, Österreich Veranstaltungsnummer: 26991 Veranstalter: Kurzbeschreibung: The 18th Congress will be held in Vienna, Austria. The scientific program will comprise a variety of symposia, poster sessions, instructional and surgical courses, video and free paper presentations and several satellite meetings. The main topics of this conference are ocular oncology for surgical and medical retina specialists, novelties and late breaking developments in retina and technology, AMD and evidence based treatment in the AntiVEGF Era. Fortbildungspunkte: 27 Fachärzte Gebühren ab: 400,00 EUR EarlyBird bis 20.09.2018: 350,00 EUR Member: Before 20 Sept - 350 20-23 Sept - 400 Non-Member: Before 20 Sept - 450 20-23 Sept - 500 Healthcare Professional: Before 20 Sept - 175 20-23 Sept - 225 Ärzte in Weiterbildung Gebühren ab: 240,00 EUR EarlyBird bis 20.09.2018: 190,00 EUR Trainee/ Resident Member: Before 20 Sept - 190 20-23 Sept - 240 Trainee/Resident Non-Member: Before 20 Sept - 210 20-23 Sept - 260 medizinisches Fachpersonal Gebühren ab: 200,00 EUR EarlyBird bis 20.09.2018: 150,00 EUR
Industriemitarbeiter Gebühren ab: 1.500,00 EUR EarlyBird bis 20.09.2018: 1.300,00 EUR Bemerkungen: Diese Veranstaltung findet jährlich statt und bietet Fortbildungsmöglichkeiten für Fachärzte, Ärzte in Weiterbildung, medizinisches Fachpersonal und Industriemitarbeiter. Die Zertifizierung wurde von der European Accreditation Council for Continuing Medical Education (EACCME) genehmigt. Sponsoren und Aussteller: Alcon Pharma GmbH Alimera Sciences Ophthalmologie GmbH Bausch + Lomb Bayer HealthCare AG D.O.R.C. Deutschland GmbH (DORC) Ellex Deutschland GmbH Heidelberg Engineering GmbH ifa systems AG MEyeTech GmbH NIDEK Inc. Novartis Pharma GmbH Optos GmbH Deutschland Pharm-Allergan GmbH Quantel Medical Roche Pharma AG Théa Pharma GmbH Topcon ZEISS Vom Veranstalter gemeldetes Programm: Thursday 20th September, 2018 Main Session 1: Ocular Oncology for surgical and medical retina specialists 09:00-10:30 Introduction S. Seregard How modern imaging can aid in the differential diagnosis of small intraocular tumours H. Heimann Intravitreal treatment of radiation - and tumor - associated macular edema L. Zografos How to diagnose intraocular lymphoma - clinical presentation and biopsy techniques N. Bornfeld Surgical resection as an alternative to enucleation in large uveal melanoma - risks and benefits N. Bechrakis Prediction of metastatic disease in patients with uveal melanoma and screening recommendations B. Damato Critical bevaluation of systemic, intracameral and opthalmic artery chemotherapy for retinoblastoma M. Sagoo Main Session 2: The guidelines for management of retinal disease 11:00-12:30 Where is anti-vegf therapy now: achievements and challenges Neovascular AMD: the ten key messages Diabetic macular edema the ten key messages Vein occlusion: the ten key messages A state-of-the-art in endophthalmitis in anti-vegf therapy The future needs and progress in anti-vegf therapy U. Schmidt-Erfurth F. Bandello A. Loewenstein A. Grzybowski D. Martin
Main Session 3: Decision making in challenging cases 14:30-16:00 Should we treat subclinical CNV discovered by OCTA? S. Schmitz-Valckenberg Is it valuable to tolerate subretinal fluid in the treatment of type 1 CNV? A. Tufail If a PDR associated with DME is treated by anti-vegf, is it safe to space out injections? Do you stop anti-vegfs in persistent RVO related CME without binocular problems? Should we operate early myopic foveoschisis to avoid complications? Can we expect visual improvement in some lamellar macular hole after surgery? What to do in chronic CSCR when serous retinal detachment reccurs after PDT? How to manage Coat's disease with central macular lipid exudation? R. Silva JR. Vingerling Y. Ikuno R. Schumann C. Boon A. Daruich-Matet Friday 21st September, 2018 Main Session 4: Novelties and late breaking developments in Retina & Technology 8:00-9:30 Recent advances in surgical techniques: new trends and expectations AI-based analysis: A revolution in imaging Genetic therapy: reinventing genes Novel understanding of normal and abnormal retinal vascularization under the light of new imagery Late Breaking Presentations Main Session 5: AMD 12:00-13:30 Dry AMD - how to proceed? Current management of exudative AMD F. Holz New studies in exudative AMD P. Dugel When can we define a patient as a non-responder A. Loewenstein Long-term effects of anti-vegf M. Goldstein Biomarkers on CNV M. Battaglia Parodi Guts, genes and AMD M. Zinkernagel Saturday 22nd September, 2018 Main Session 6:PDR in 2018: Evidence based treatment in the AntiVEGF Era 8:00-9:30 Pathophysiology of macular edema, diabetic and other M. Larsen Retinal photocoagulation : Pro and Cons E. Pilotto Anti VEGF and proliferative diabetic retinopathy trial data: S. Sivaprasad / J. Wells How might Protocol S and Clarity results be generalized in current practice R. Schlingemann Cost effectiveness of antivegf therapy for PDR N. Bressler Vitrectomy in PDR 2018 D. Steel Chaired panel discussion on pragmatic evidence based management of PDR in 2018 (specific scenarios): i. Severe NPDR, treat don t treat? ii. Low risk NVD/E treat don t treat: what with? iii. HRC: no macular edema iv. HRC: with macular edema v. Persistent NV after standard PRP vi. Mild vitreous haemorrhage after full PRP vii. Florid PDR with no previous treatment
Main Session 7: Imaging 16:30 Agreement between OCT angiography and FA/ICG in neovascular AMD U. Chakravarthy Single layer OCT, OCT angiography and fuctional correlates in diabetic patients E. Midena Retinal vascular biomakers foralzheimer's disease T. Peto Adaptive optics-slo single photoreceptor imaging and Psychophysics W. Harmening The use of artificial intelligence / deep learning in the analysis of retinal images P. Keane Full volume render virtual reality OCT P. Maloca Main Session 8: Research Session 11:00-12:30 Genetics in retinal disease B. LeRoy Genetics in retinal disease Gene therapy achromatopsia CNGA3 Gene therapy achromatopsia CNGB3 Optogenetics for end-stage retinis pigmentosa (2 perspectives) Cell therapy for age-related macular degeneration Gene therapy for retinis pigmentosa The Argus II retinal implant for retinis pigmentosa The AMS epiretinal implant for retinis pigmentosa C.C.W. Klaver D. Fischer J. Bainbridge S. Kleinlogel R. MacLaren S. Rizzo F. Gekeler Sunday 23 September, 2018 Main Session 9: Vitreoretinal surgery 10:00-11:30 Retinal detachment outcomes in IRIS (Intelligent research in sight) Intraocular foreign body removal: Tips and tricks Paediatric retinal detachment Surgical management of optic pit maculopathy: Which is the best technique? Endoillumination buckle Cold-fusion Retinopathy of prematurity S. Chien Wong J. Garcia Arumi Main Session 10: Myopia - a full update 12:00-13:30 Genetics, risk factors and epidemiology of myopia C.C.W. Klawer Progression of myopia and myopic maculopathy J. Jonas Prevention of myopia and of ist evolution G. Cheung Refractive and lens surgery in highly myopic eyes and lens from the retina perspective Modern imaging of the retina in high myopia Domeshape macula news Myopic choroidal neovascularization management update Update on modern surgery in highly myopic eyes to achieve best possible results New technics for closing myopic macular holes A. Grzybowski Y. lida G. Querques R. Tadayoni M. Figueroa Meet the Experts, OD-OS Navilas Booth C207 Friday, September 21st 2018 10:00 am - D. Maltsev - Macroaneurysms Saturday, September 22nd 2018 10:00 am - J. Chhablani - MSP vs. PDT for CSCR 13:30 pm - I. Kozak - Coat's Disease Sunday, September 23rd 2018
10:00 am - F. Amorosa - The future of PRP Treatment Veranstaltungsort: Reed Messe Wien Anschrift: Messepl. 1 1020 Wien, Österreich Veranstalter: Organisation: Temple House Temple Road, Blackrock Tel.: +353 (0)1 210 0092 Fax: +353 (0)1 209 1112 Anmeldung: Diese Veranstaltung können Sie derzeit nicht über EYEFOX buchen.